СПОСОБ ИНДИВИДУАЛЬНОГО ПОДБОРА ПОДДЕРЖИВАЮЩЕЙ ДОЗЫ ЛЕВОСИМЕНДАНА ДЛЯ ЛЕЧЕНИЯ ОСТРОЙ СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТИ У ПОЖИЛЫХ БОЛЬНЫХ В ОСТРОЙ СТАДИИ ИНФАРКТА МИОКАРДА
Tepljakov Aleksandr Trofimovich,Тепляков Александр Трофимович,Tarasov Nikolaj Ivanovich,Тарасов Николай Иванович,Grakova Elena Viktorovna,Гракова Елена Викторовна,Sinkova Margarita Nikolaevna,Синькова
申请号：
RU2015136553/14
公开号：
RU0002601666C1
申请日:
2015.08.27
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to cardiology. Sequential pharmacological test is performed and blood pressure (BP) and heart rate (HR) are measured and electrocardiogram (ECG) is analyzed. Pharmacological test is carried out in three stages. First stage involves introduction of a loading bolus of 4 mcg/kg of levosimendan for 10 minutes which is equal to 1/3 of the standard value and if BP is not less than 100 mm Hg, HR is not more than 100 beats per minute, paroxysmal atrial fibrillation (AF) and ventricular tachycardia are absent, the second stage of the test begins. Patients with BR, HR and ECG parameters that do not match the specified values are prescribed the infusion of levosimendan at the minimum supporting dosage of 0.05 mcg/kg/min. Second stage involves introduction of loading bolus of 4 mcg/kg of levosimendan for 10 minutes which is equal to 2/3 of the standard values and if BP is not less than 100 mm Hg, HR is not more than 100 beats per minute and paroxysmal atrial fibrillation and ventricular tachycardia are absent, the third stage of the test begins. Patients with BR, HR and ECG parameters that do not match the specified values are prescribed the infusion of levosimendan at the minimum supporting dosage of 0.1 mcg/kg/min. Third stage involves introduction of loading bolus of 4 mcg/kg of levosimendan for 10 minutes which is a standard recommended dose of 12 mcg/kg and if BP is not less than 100 mm Hg, HR is not more than 100 beats per minute and paroxysmal atrial fibrillation and ventricular tachycardia are absent, an optimum supporting dose of levosimendan in an amount of 0.15 mcg/kg/min for 27-34 hours is introduced until the total dose of levosimendan equalling is achieved 12.5 mg.EFFECT: method enables higher effectiveness of treatment of acute cardiac failure ensuring considerable reduction of the hospital and remote lethality during 12 months of observation, frequency and severity of coronary insufficiency, chroni
